{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:58:25Z","timestamp":1774378705376,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01354","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T05:22:12Z","timestamp":1597814532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Ram N.","family":"Ganapathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley P.","family":"Sutker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin E.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahrukh K.","family":"Ganapathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1200\/JCO.19.00314","article-title":"Advances in the management of platinum-sensitive relapsed ovarian cancer","volume":"37","author":"Bouberhan","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMe1914488","article-title":"Personalized medicine for primary treatment of serous ovarian cancer","volume":"381","author":"Longo","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e45440","DOI":"10.15252\/embr.201745440","article-title":"Perturbing mitosis for anti-cancer therapy: is cell death the only answer?","volume":"19","author":"Haschka","year":"2018","journal-title":"EMBO Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.canlet.2018.10.005","article-title":"Mitosis inhibitors in anticancer therapy: when blocking the exit becomes a solution","volume":"440","author":"Henriques","year":"2019","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","first-page":"jcs191353","DOI":"10.1242\/jcs.191353","article-title":"Aurora A kinase activity is required to maintain an active spindle assembly checkpoint during prometaphase","volume":"131","author":"Courtheoux","year":"2018","journal-title":"J Cell Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2015.00295","article-title":"Aurora-A kinase as a promising therapeutic target in cancer","volume":"5","author":"D'Assoro","year":"2016","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/jjco\/hyv058","article-title":"Prognostic value of aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fonc.2015.00189","article-title":"Scientific rationale supporting the clinical development strategy for the investigational aurora A kinase inhibitor alisertib in cancer","volume":"5","author":"Niu","year":"2015","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","article-title":"Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors","volume":"27","author":"Liewer","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-11-0623","article-title":"The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells","volume":"11","author":"Sehdev","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1158\/1535-7163.MCT-14-0027","article-title":"Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational aurora A kinase inhibitor MLN8237 (alisertib)","volume":"13","author":"Huck","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/1878-0261.12066","article-title":"Cisplatin-resistant cancer cells are sensitive to aurora kinase A inhibition by alisertib","volume":"11","author":"Wang","year":"2017","journal-title":"Mol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0090-8258(03)00481-5","article-title":"Apoptotic pathways of epothilone BMS 310705","volume":"91","author":"Uyar","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B17","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/sj.bjc.6602662","article-title":"Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability","volume":"93","author":"Maeda","year":"2005","journal-title":"Br J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/nprot.2012.097","article-title":"Primary culture and immortalization of human fallopian tube secretory epithelial cells","volume":"7","author":"Karst","year":"2012","journal-title":"Nat Protoc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1074\/jbc.M009831200","article-title":"Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human non-small cell lung carcinoma","volume":"276","author":"Tabata","year":"2001","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1756-9966-29-159","article-title":"Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells","volume":"29","author":"Wang","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ygyno.2018.01.022","article-title":"HOXA4\/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy","volume":"149","author":"Miller","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3109\/10715762.2011.591391","article-title":"Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells","volume":"45","author":"Itoh","year":"2011","journal-title":"Free Radic Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.freeradbiomed.2010.05.031","article-title":"Uncoupling protein-2 knockdown mediates the cytotoxic effects of cisplatin","volume":"49","author":"Santandreu","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3324\/haematol.2016.158394","article-title":"Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia","volume":"102","author":"Fathi","year":"2017","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2003","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.4161\/cc.8.6.7897","article-title":"The inhibition of aurora A abrogates the mitotic delay induced by microtubule perturbing agents","volume":"8","author":"Wysong","year":"2009","journal-title":"Cell Cycle"},{"key":"B29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.18632\/aging.101291","article-title":"AURKA inhibition mimics BRCAness","volume":"9","author":"Hirst","year":"2017","journal-title":"Aging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/2211-5463.12087","article-title":"Aurora A kinase is required for activation of the fanconi anemia\/BRCA pathway upon DNA damage","volume":"6","author":"Chun","year":"2016","journal-title":"FEBS Open Bio"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/0008-5472.CAN-04-3981","article-title":"RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells","volume":"65","author":"Hata","year":"2005","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T05:22:14Z","timestamp":1597814534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":33,"alternative-id":["10.3389\/fonc.2020.01354"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01354","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"article-number":"1354"}}